IN THE CLAIMS

Kindly cancel claims 74-88, 90, 91, 95-99 and 103-105 without prejudice.

Kindly add the following claims*:

106. (Added) The method according to claim 67, wherein the morphogenic protein comprises a pair of subunits disulfide bonded to produce a dimeric species and wherein at least one of the subunits comprises a polypeptide belonging to the BMP protein family.

107. (Added) The method according to claim 67, wherein the morphogenic protein is an osteogenic protein.

108. (Added) The method according to claim 107, wherein the osteogenic protein is capable of inducing the progenitor cell to form endochondral or intramembranous bone.

109. (Added) The method according to claim 107, wherein the osteogenic protein is capable of inducing the progenitor cell to form cartilage.

110. (Added) The method according to claim 69, wherein the morphogenic protein is capable of inducing the progenitor cell to form tissue tendon/ligament-like or neural-like tissue.

---

* An "Appendix of Amendments" is attached as Exhibit A, showing the claim amendments.

111. (Added) The method according to claim 69, wherein the morphogenic protein comprises a polypeptide selected from the group consisting of: BMP-2, BMP-4, BMP-5, BMP-6, BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, and BMP-13, COP-5, COP-7.

112. (Added) The method according to claim 69, wherein the morphogenic protein comprises a polypeptide selected from the group consisting of BMP-7 (OP-1), BMP-2, BMP-4 and BMP-6.

113. (Added) The method according to claim 69, wherein the morphogenic protein comprises BMP-7 (OP-1).

E1

114. (Added) The method according to claim 106, wherein the dimeric species is a homo- or hetero-dimer comprising at least one BMP-2 or BMP-7 (OP-1) subunit.

115. (Added) The method according to claim 69, wherein the morphogenic protein stimulatory factor is IGF-I.

116. (Added) The method according to claim 69, wherein the morphogenic protein is present in the pharmaceutical composition at a concentration of at least about 1 ng/ml, and the morphogenic protein stimulatory factor is present in the pharmaceutical composition at a concentration of at least about 0.01 ng/ml.

117. (Added) The method according to claim 69, wherein the morphogenic protein is BMP-7 (OP-1) and is present in the pharmaceutical composition at a concentration of from about 1 ng/ml to about 500 ng/ml

and the morphogenic protein stimulatory factor is IGF-I and is present in the pharmaceutical composition at a concentration of from about 0.1 ng/ml to about 50 ng/ml.

118. (Added) The method according to claim 69, wherein the morphogenic protein is BMP-7 (OP-1) and is present in the pharmaceutical composition at a concentration of from about 1 ng/ml to about 500 ng/ml and the morphogenic protein stimulatory factor is hydrocortisone and is present in the pharmaceutical composition at a concentration of from about 0.05 nM to about 5.0 nM.

119. (Added) The method according to claim 118, wherein BMP-7 (OP-1) is about 200 ng/ml and hydrocortisone is about 0.5 - 5.0 nM.

E1

120. (Added) The method according to claim 69, wherein the morphogenic protein is BMP-7 (OP-1) and is present in the pharmaceutical composition at a concentration of from about 1 ng/ml to about 500 ng/ml and the morphogenic protein stimulatory factor is insulin and is present in the pharmaceutical composition at a concentration of from about 0.01 nM to about 1000 nM.

121. (Added) The method according to claim 69, wherein the morphogenic protein is BMP-7 (OP-1) and is present in the pharmaceutical composition at a concentration of from about 1 ng/ml to about 500 ng/ml and the morphogenic protein stimulatory factor is parathyroid hormone and is present in the pharmaceutical composition at a concentration of from about 10 nM to about 1000 nM.